Présentation de l'entreprise
PMGC Holdings Inc. operates as a biopharmaceutical entity dedicated to the research, development, and acquisition of advanced aesthetic medicines and therapeutic products designed to address specific medical needs. The company functions within the broader Healthcare sector, specifically targeting the Biotechnology industry, where it seeks to innovate in the field of engineered probiotics and therapeutic solutions. As a private-market entity with a market capitalization of $8.72M, the company employs 32 individuals and generated total revenue of $590,084 over the trailing twelve months. The combination of a market cap under $10 million and annual revenue below $1 million indicates that PMGC Holdings Inc. is a micro-cap company with a very small market footprint, suggesting significant early-stage growth potential or limited commercialization progress relative to its peers.
Santé financière
The company reported a revenue of $590,084 for the trailing twelve months, yet recorded a net income loss of $-7,780,740 and an EBITDA of $-7,026,714, highlighting a substantial disparity between top-line generation and bottom-line profitability. This massive gap between the modest revenue figure and the deep net income loss reveals a highly aggressive cost structure typical of early-stage biotechnology firms, where research and development expenditures far exceed current sales proceeds. The company's financial flexibility is currently constrained, as evidenced by a free cash flow of $-2,762,601, indicating that operational cash outflows are consuming the company's liquidity reserves to fund its ongoing development activities. Furthermore, the balance sheet presents a complex picture with cash holdings of $6.07M offsetting a total debt load of $2.64M, while maintaining a debt-to-equity ratio of 33.75 that reflects a leveraged position relative to shareholder equity. Despite the leverage, the current ratio stands at 1.74, which suggests that the company possesses adequate short-term liquidity to cover its immediate obligations without immediate distress. However, the return on equity is reported at -107.3% and the return on assets at -40.7%, metrics that indicate management has yet to generate positive returns on the capital deployed for the company's operations and asset base.
Évaluation de la valorisation
Valuation multiples for PMGC Holdings Inc. are presented as N/A for both the trailing P/E ratio and the forward P/E ratio, a status that implies earnings are not yet sufficient to support a traditional price-to-earnings multiple based on current or projected profitability. The price-to-book ratio is recorded at 0.05, which indicates that the market values the company's equity at a fraction of its book value, reflecting the high risk associated with its unproven revenue streams and negative earnings history. Alternative valuation metrics such as the price-to-sales ratio of 14.77 and the EV/EBITDA of -0.26 suggest that investors are pricing the company based on future growth expectations rather than current financial performance, despite the negative earnings trajectory. The stock's trading range over the past year spans from a 52-week low of $1.62 to a 52-week high of $467.37, illustrating extreme price volatility. Based on the available data points, the current price position relative to this wide range suggests the asset is trading significantly below its recent highs, though the specific current price is not provided to calculate an exact percentage deviation. The beta coefficient is listed as 0.71, which indicates that the stock's price volatility is theoretically lower than the broader market average, although the massive spread between the 52-week high and low contradicts a standard interpretation of low beta in a liquid market.
Growth & Income
The revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, preventing a direct comparison of earnings growth speed relative to revenue expansion due to the lack of historical comparative data in the current reporting period. Consequently, it is impossible to determine from the provided facts whether earnings are growing faster or slower than revenue, as the necessary baseline figures for calculation are not available in the dataset. Regarding income generation, the company does not distribute dividends to shareholders, evidenced by a dividend yield of N/A and a payout ratio of 0.0%. This absence of dividend payments implies that the company retains all available earnings to reinvest into research, development, and the acquisition of new therapeutic products rather than distributing income to investors. The overall growth and income profile for PMGC Holdings Inc. is characterized by a focus on capital appreciation and product development rather than current income generation or steady revenue expansion.